KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Resmed (RMD) EBIAT (2016 - 2025)

Resmed (RMD) has disclosed EBIAT for 17 consecutive years, with $392.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 13.92% year-over-year to $392.6 million, compared with a TTM value of $1.5 billion through Dec 2025, up 18.99%, and an annual FY2025 reading of $1.4 billion, up 37.2% over the prior year.
  • EBIAT was $392.6 million for Q4 2025 at Resmed, up from $348.5 million in the prior quarter.
  • Across five years, EBIAT topped out at $392.6 million in Q4 2025 and bottomed at -$78.5 million in Q1 2021.
  • Average EBIAT over 5 years is $247.8 million, with a median of $227.3 million recorded in 2022.
  • The sharpest move saw EBIAT tumbled 148.11% in 2021, then surged 328.1% in 2022.
  • Year by year, EBIAT stood at $201.8 million in 2021, then increased by 11.48% to $224.9 million in 2022, then fell by 7.16% to $208.8 million in 2023, then surged by 65.05% to $344.6 million in 2024, then grew by 13.92% to $392.6 million in 2025.
  • Business Quant data shows EBIAT for RMD at $392.6 million in Q4 2025, $348.5 million in Q3 2025, and $379.7 million in Q2 2025.